Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPC-02
- Development stage
- Preclinical
- Lead developer
- Spectrum Antimicrobials
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
SPC-02 is a preclinical-stage antimicrobial therapeutic being developed by Collidion and its subsidiary, Spectrum Antimicrobials. The candidate utilizes a proprietary "Weaponized Protein Technology" to deliver hypochlorous acid (HOCl), a potent oxidative agent, to the site of infection. SPC-02 is specifically designed to combat antibiotic-resistant bacteria (superbugs) and penetrate bacterial biofilms, which are significant barriers to conventional antibiotic efficacy. The mechanism involves the rapid oxidation of bacterial components, leading to cell death without the typical resistance mechanisms associated with traditional antibiotics.
Beyond the preview
Go deeper on SPC-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPC-02.